Market Size of Middle East and Africa Insulin Syringe Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 0.89 Billion |
| Market Size (2029) | USD 1.07 Billion |
| CAGR (2024 - 2029) | 3.81 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MEA Insulin Syringe Market Analysis
The Middle East and Africa Insulin Syringe Market size is estimated at USD 0.89 billion in 2024, and is expected to reach USD 1.07 billion by 2029, growing at a CAGR of 3.81% during the forecast period (2024-2029).
The market is estimated to reach a value of more than USD 1 billion by 2027.
The COVID-19 pandemic positively impacted the Insulin Syringe market growth in the Middle East and African region. Patients with diabetes, infected with SARS-CoV-2 experience additional stress and increased secretion of hyperglycemic hormones, which results in elevated blood glucose, abnormal glucose variability, and diabetic complications. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Diabetes is associated with many health complications. To avoid complications, a patient's blood glucose level should be maintained at a normal level.
Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. The manufacturers of Insulin Syringes have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments.
Diabetes poses an emerging healthcare burden across the region. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy.
Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
MEA Insulin Syringe Industry Segmentation
Insulin syringes are used for self-injection and are available in multiple sizes to help deliver different doses of insulin. The Middle East and Africa insulin syringe market is segmented by geography (Egypt, Oman, Saudi Arabia, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD million) and volume (in units million) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Geography | |
| Egypt | |
| Iran | |
| Oman | |
| Saudi Arabia | |
| South Africa | |
| Rest of Middle East and Africa |
Middle East and Africa Insulin Syringe Market Size Summary
The Middle East and Africa insulin syringe market is poised for growth, driven by the increasing prevalence of diabetes and the need for effective blood glucose management. The market is experiencing a positive impact from the COVID-19 pandemic, as individuals with diabetes require more frequent insulin administration to manage elevated blood glucose levels. This has led to a heightened demand for insulin syringes, supported by manufacturers' efforts to ensure the availability of these devices through collaboration with local governments. The region's diabetes population is expected to rise significantly, prompting governments to implement various policies and initiatives to address this healthcare challenge. Despite these efforts, the lack of comprehensive national strategies in some countries continues to pose a challenge, highlighting the need for ongoing measures to mitigate diabetic complications.
Iran holds a significant share of the market, with a notable prevalence of diabetes that poses economic and health challenges. The country's diabetes management efforts are hindered by socio-demographic factors, necessitating targeted strategies for prevention and control. The market is moderately fragmented, with major players like Becton Dickinson and Terumo Corporation driving innovation and market competition through both organic and inorganic growth strategies. Recent developments, such as the integration of connected technology for tracking drug therapy adherence and the launch of specialized syringes for biotech products, underscore the industry's commitment to advancing insulin delivery solutions. These initiatives, along with increased awareness and the roll-out of new products, present opportunities for market players to expand their presence in the region.
Middle East and Africa Insulin Syringe Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Insulin Syringe
-
2.2 Geography
-
2.2.1 Egypt
-
2.2.2 Iran
-
2.2.3 Oman
-
2.2.4 Saudi Arabia
-
2.2.5 South Africa
-
2.2.6 Rest of Middle East and Africa
-
-
Middle East and Africa Insulin Syringe Market Size FAQs
How big is the Middle East and Africa Insulin Syringe Market?
The Middle East and Africa Insulin Syringe Market size is expected to reach USD 0.89 billion in 2024 and grow at a CAGR of 3.81% to reach USD 1.07 billion by 2029.
What is the current Middle East and Africa Insulin Syringe Market size?
In 2024, the Middle East and Africa Insulin Syringe Market size is expected to reach USD 0.89 billion.
